Immune Design
Nov 11, 2015

Immune Design to Present at Jefferies Autumn 2015 Global Healthcare Conference in London

SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies Autumn 2015 Global Healthcare Conference on Wednesday, November 18, 2015 at 12:40 p.m. GMT, 7:40 a.m. Eastern time, in London.

A live webcast of the presentation will be available online from the investor relations page of the company's corporate website at After the live webcast, an archive of each presentation will be available on the company website.

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the two-pronged focus of Immune Design's ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms, ZVexTM and GLAASTM. Immune Design has offices in Seattle and South San Francisco. For more information, visit

CONTACT: Media Contact

         Julie Rathbun

         Rathbun Communications


         Investor Contact

         Shari Annes

         Annes Associates


company logo

Source: Immune Design

News Provided by Acquire Media